Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

AbbVie's deal with RemeGen is the first to be announced during the 2026 J.P Morgan Healthcare Conference, with more deals ...

First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of ...

Summit Therapeutics Inc. ( SMMT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM EST ...

RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancersNORTH CHICAGO, Ill.

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

Detailed price information for Arcus Biosciences Inc (RCUS-N) from The Globe and Mail including charting and trades.

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...